Medtronic

Medtronic to announce financial results for its fourth quarter and full fiscal year 2024

Retrieved on: 
星期四, 五月 9, 2024
Central Time Zone, CDT, Medtronic, Webcast, News

DUBLIN, May 9, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2024 on Thursday, May 23, 2024.

Key Points: 
  • DUBLIN, May 9, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2024 on Thursday, May 23, 2024.
  • The news release will include summary financial information for the company's fourth quarter and full fiscal year 2024, which ended on Friday, April 26, 2024.
  • Medtronic will host a video webcast at 7:00 a.m. CDT on Thursday, May 23, 2024, to discuss results for its fourth quarter and full fiscal year 2024.
  • Looking ahead, Medtronic plans to report its first, second, third, and fourth quarter fiscal year 2025 results on Tuesday, August 20, 2024, Tuesday, November 19, 2024, Tuesday, February 18, 2025, and Thursday, May 22, 2025, respectively.

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall

Retrieved on: 
星期四, 五月 9, 2024
FDA, SOS, Mouth, Cell, Risk, Obstruction, Stomach, Lucid, Collection, Research, Medtronic, Patient, Esophagus, Airway obstruction, Cancer, Medical device

NEW YORK, May 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), announced that the legacy EsophaCap sponge-on-a-string (SOS) esophageal cell collection device, which it briefly supplied to third-party institutions for their own research studies, has been subjected to a Class II FDA recall due to two serious device failures reported in a recent publication of one of these studies. EsophaCap is not a commercial Lucid product.

Key Points: 
  • In addition, troubling reports of serious device failures have plagued SOS devices for many years, leading to multiple Class II FDA recalls similar to this one.
  • Dr. Aklog added, "In stark contrast, Lucid's EsoCheck® Esophageal Cell Collection Device , with its patent-protected Collect+Protect™ technology, is a modern groundbreaking technology.
  • These detachments were similar to previously-reported detachments of the Cytosponge Cell Collection Device, an SOS manufactured by Medtronic, which led to two Class II FDA recalls, including a June 2023 open global recall , which remains in effect.
  • As the manufacturer of record, Lucid proactively informed the FDA of the reported device failures and concluded that a Class II recall of the EsophaCap SOS was necessary and was made effective as of April 25, 2024.

Cronos Group Reports 2024 First Quarter Results

Retrieved on: 
星期四, 五月 9, 2024
Cream, Mazor Robotics, Genetics, Certified Public Accountant, Wedding cake, Investment, Fully Charged, Average cost, Capital, EY, Pharma, Depreciation, Cannabinol, Flower, Robotics, Traction, GMO, Partnership, Research, Capital expenditure, Medtronic, Tax, Senior, Patient, Vii, Hamas, CBC, Motus, CBN, Lord, CBG, Growth, Drug

TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announces its 2024 first quarter business results.

Key Points: 
  • Cronos Growing Company Inc. ("Cronos GrowCo") reported to the Company preliminary unaudited net revenue to licensed producers, excluding sales to the Company, of approximately $5.1 million in the first quarter of 2024.
  • Cronos previously provided Cronos GrowCo with a senior secured credit facility, which currently has approximately $67.1 million outstanding following a principal repayment of $1.2 million by Cronos GrowCo in Q1 2024.
  • In addition to principal repayment, Cronos also received $1.4 million in interest payments from Cronos GrowCo, totaling approximately $2.7 million in cash payments to Cronos in Q1 2024.
  • Before becoming Head of Cronos Israel, he was the Vice President of Finance at Cronos Israel managing the Cronos Israel finance department.

Electrosurgery Market to be Worth $8.99 Billion by 2031 - Exclusive Report by Meticulous Research®

Retrieved on: 
星期三, 五月 8, 2024
Smoke, United Nations, Risk, General surgery, Surgeon, Electrosurgery, Medtronic, Smith, Olympus Corporation, Boston Scientific, Lip, Perforation, Prevalence, Skin, Medical tourism, Spine, Obstetrics, Ageing, Argon, Plasma, Conditional sentence, Hospital, Generator, Geography, ENT, Johnson & Johnson, Bleeding, Incidence, Government, BPH, Stryker Corporation, Steris, ASC, Disease, United, Patient, Coagulation, Circulatory system, Cancer, Growth, Dentistry

Additionally, factors such as rising healthcare expenditure and market expansion in emerging economies are expected to create market growth opportunities.

Key Points: 
  • Additionally, factors such as rising healthcare expenditure and market expansion in emerging economies are expected to create market growth opportunities.
  • However, the risks associated with electrosurgical procedures and the shortage of surgeons restrain the growth of this market.
  • The report also includes an extensive assessment of the key growth strategies adopted by leading market players over the past three years.
  • The global electrosurgery market has witnessed several product launches, product approvals, acquisitions, and expansions in the last couple of years.

Electrosurgery Market to be Worth $8.99 Billion by 2031 - Exclusive Report by Meticulous Research®

Retrieved on: 
星期三, 五月 8, 2024
Smoke, United Nations, Risk, General surgery, Surgeon, Electrosurgery, Medtronic, Smith, Olympus Corporation, Boston Scientific, Lip, Perforation, Prevalence, Skin, Medical tourism, Spine, Obstetrics, Ageing, Argon, Plasma, Conditional sentence, Hospital, Generator, Geography, ENT, Johnson & Johnson, Bleeding, Incidence, Government, BPH, Stryker Corporation, Steris, ASC, Disease, United, Patient, Coagulation, Circulatory system, Cancer, Growth, Dentistry

Additionally, factors such as rising healthcare expenditure and market expansion in emerging economies are expected to create market growth opportunities.

Key Points: 
  • Additionally, factors such as rising healthcare expenditure and market expansion in emerging economies are expected to create market growth opportunities.
  • However, the risks associated with electrosurgical procedures and the shortage of surgeons restrain the growth of this market.
  • The report also includes an extensive assessment of the key growth strategies adopted by leading market players over the past three years.
  • The global electrosurgery market has witnessed several product launches, product approvals, acquisitions, and expansions in the last couple of years.

Remote Patient Monitoring Market to Be Worth $116.84 Billion by 2031 - Exclusive Report by Meticulous Research®

Retrieved on: 
星期一, 五月 6, 2024
Telehealth, World Health Organization, Partnership, Abbott Laboratories, Intelligence, Medtronic, Privacy, Boston Scientific, Prevalence, WHO, Dexcom, Machine learning, Literacy, Vital signs, Omron, Wearable computer, Blood pressure, Ageing, Diabetes, Conditional sentence, RPM, Fear, Artificial intelligence, Function, Incidence, Geography, Blood, DSM-IV codes, Health care, Patient, Mechanical ventilation, Oracle Corporation, COVID-19, Growth, Medical device

Thus, the integration of AI in remote patient monitoring is expected to improve patient experience, boosting the adoption of remote patient monitoring solutions.

Key Points: 
  • Thus, the integration of AI in remote patient monitoring is expected to improve patient experience, boosting the adoption of remote patient monitoring solutions.
  • Geographically, in 2024, North America is expected to account for the largest share of 44% of the remote patient monitoring market.
  • The North America remote patient monitoring market is estimated to be worth USD 21.2 billion in 2024.
  • The global remote patient monitoring market has witnessed product launches, product approvals, collaborations, acquisitions, and expansions in the last couple of years.

Remote Patient Monitoring Market to Be Worth $116.84 Billion by 2031 - Exclusive Report by Meticulous Research®

Retrieved on: 
星期一, 五月 6, 2024
Telehealth, World Health Organization, Partnership, Abbott Laboratories, Intelligence, Medtronic, Privacy, Boston Scientific, Prevalence, WHO, Dexcom, Machine learning, Literacy, Vital signs, Omron, Wearable computer, Blood pressure, Ageing, Diabetes, Conditional sentence, RPM, Fear, Artificial intelligence, Function, Incidence, Geography, Blood, DSM-IV codes, Health care, Patient, Mechanical ventilation, Oracle Corporation, COVID-19, Growth, Medical device

Thus, the integration of AI in remote patient monitoring is expected to improve patient experience, boosting the adoption of remote patient monitoring solutions.

Key Points: 
  • Thus, the integration of AI in remote patient monitoring is expected to improve patient experience, boosting the adoption of remote patient monitoring solutions.
  • Geographically, in 2024, North America is expected to account for the largest share of 44% of the remote patient monitoring market.
  • The North America remote patient monitoring market is estimated to be worth USD 21.2 billion in 2024.
  • The global remote patient monitoring market has witnessed product launches, product approvals, collaborations, acquisitions, and expansions in the last couple of years.

Memorial Neuroscience Institute First in South Florida to Utilize Latest Aneurysm Treatment Technology

Retrieved on: 
星期一, 四月 29, 2024
Leg, FDA, Brain, Aneurysm, Stroke, Bleeding, Permanent Damage, Safety, Neck, Survival, Interventional neuroradiology, Arm, Medtronic, Spine, Patient, Wrist, Headache, Physician, Memorial Hermann Health System, Epilepsy, Neoplasm, Multiple sclerosis, Diagnosis, Rehabilitation, Multimedia, Human, Mehta, Medical imaging

HOLLYWOOD, Fla., April 29, 2024 /PRNewswire-PRWeb/ -- As a veterinarian in Cuba, Xiomara Delgado was used to providing clinical expertise to patients and families. Now retired and living in Miami, the 77-year-old doctor was recently on the other side of a diagnosis, and it wasn't a good one.

Key Points: 
  • - Dr. Brijesh P. Mehta
    Delgado periodically suffered from very painful headaches that were severe enough to require a visit to Memorial.
  • Delgado was immediately referred to Dr. Brijesh P Mehta , medical director of Neurointerventional Surgery and the Comprehensive Stroke Program at Memorial Neuroscience Institute.
  • Mehta is one of approximately 20 physicians in the U.S. trained to use Medtronic's Pipeline Vantage device for treatment of brain aneurysms.
  • Memorial Neuroscience Institute offers advanced diagnoses, comprehensive treatment, compassionate care, and rehabilitation for complex neurological conditions.

Affluent Medical : 2023 financial results and update on clinical activities under development.

Retrieved on: 
星期五, 五月 3, 2024
Medtech, FDA, Risk, De novo, Death, Mitral regurgitation, Doctor of Philosophy, Wound healing, Mitral valve annuloplasty, Boston Scientific, Ticker, Wealth, Urinary incontinence, Woman, Christophe, Food, Neurostimulation, Myocardial infarction, Aix-en-Provence, DSM-IV codes, LCEA, Mitral valve, TAVI, Minerva, Certification, Heart, Quality assurance, System, Anatomy, Exercise, NYHA, Dry, Marketing, Clinical trial, American College, Development director, MD, Endocarditis, Medtronic, Patient, Tricuspid valve, Acquisition, Medical device

Affluent Medical : 2023 financial results and update on clinical activities under development.

Key Points: 
  • Affluent Medical : 2023 financial results and update on clinical activities under development.
  • Affluent Medical estimates that KaliosTM would avoid repeat surgery for 30-40% of patients within five years of their operation.
  • In September 2023, the Company presented interim data on 20 patients treated in five clinical centers in Europe after one year of implantation.
  • In July 2023, Affluent Medical announced the appointments of Christophe de Vregille as Chief Financial Officer and Benjamin Renault as Development Director.

Tactile Medical Announces CEO Transition and Preliminary First Quarter 2024 Revenue

Retrieved on: 
星期二, 四月 23, 2024
World Health Organization, Policy, Johnson & Johnson, Health care, Webcast, Human, Medtronic, TCMD, Patient, Bank statement, Tactile, Growth

Concurrently, the Company announced the appointment of Sheri Dodd, a member of the Company’s board of directors, as Chief Executive Officer, effective July 1, 2024.

Key Points: 
  • Concurrently, the Company announced the appointment of Sheri Dodd, a member of the Company’s board of directors, as Chief Executive Officer, effective July 1, 2024.
  • Sheri has been a thoughtful and respected voice on our board, and I am confident Tactile will benefit from her leadership as our new CEO,” said William W. Burke, Chairman of the board of Tactile Medical.
  • “I look forward to working with Sheri and the board of directors to build upon the foundation we’ve established and create additional shareholder value.”
    The Company also announced preliminary unaudited first quarter 2024 total revenue.
  • Total revenue for the first quarter of 2024 is expected to be approximately $61 million, compared to $58.8 million in the first quarter of 2023.